New oral PCSK-9 inhibitor demonstrates efficacy and safety
The small molecule AZD0780, binding to and causing inhibition of the enzyme PCSK-9, has demonstrated efficacy and safety in the treatment of high cholesterol levels.
PCSK-9 inhibitors were previously only injected subcutaneously once every 14 days in the case of Praluent and Repatha and twice a year in the case of Leqvio. However, the newly validated AZD 0780 is intended for oral use once daily and is thus the first PCSK-9 inhibitor intended for oral use.
The favourable data were published in the literature and presented at this year's American Heart Association Congress.
